bebt-209
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 15, 2019 (NCT06047184)
Timeline
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06685796 | Phase 2 | Apr 12, 2023 | Central South University, Guangzhou BeBetter Medicine Technology Co, LTD, Sun Yat-Sen University |
| NCT06998108 | Phase 3 | Jun 9, 2022 | Chinese Academy of Medical Sciences, Guangzhou BeBetter Medicine Technology Co, LTD |
| NCT06047184 | Phase 1 | Jul 15, 2019 | Central South University, Guangzhou BeBetter Medicine Technology Co, LTD |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou BeBetter Medicine Technology Co, LTD | For profit | 3 | 3 | 3 | 2019 |
| Central South University | Academic/Hospital | 2 | 0 | 2 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1